Seattle, United States
A-Alpha Bio, known as "The protein-protein interaction company," is a pioneering entity in the biotechnology industry focused on the large-scale measurement, prediction, and engineering of protein-protein interactions.
Founded in 2017 and based in the United States, this innovative company utilizes its proprietary platform, AlphaSeq, for rapid and quantitative analysis of protein-binding affinities, and AlphaBind, an AI-fueled tool that predicts binding strengths using the world's largest protein interaction database.
With a strategic approach towards collaboration, A-Alpha Bio partners with pharmaceutical and biotechnology organizations to develop dual-specific and molecular glue therapeutics, optimize biologics, and amass vital protein data for AI model enhancement.
The company recently secured a $14.50M investment from the U.S. Department of Defense on May 21, 2024, marking a significant milestone in its quest to revolutionize health care and life sciences through advanced biotechnological solutions.
Liberum Biotech